James Gilham
Impact in
- Infectious Diseases top 10%
- COVID-19 Clinical Research Studies
- SARS-CoV-2 and COVID-19 Research
-
- Diabetes Treatment and Management
Papers in
-
- COVID-19 Clinical Research Studies 5
-
- Diabetes Treatment and Management 1
James Gilham
7 papers receiving 373 citations
James Gilham's Hit Papers
Peers
Comparison fields: 5 of 48
- Infectious Diseases 230
- Endocrinology, Diabetes and Metabolism 28
- Pulmonary and Respiratory Medicine 28
- Epidemiology 28
- Geriatrics and Gerontology 3
Countries citing papers authored by James Gilham
This map shows the geographic impact of James Gilham's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by James Gilham with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites James Gilham more than expected).
Fields of papers citing papers by James Gilham
This network shows the impact of papers produced by James Gilham. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by James Gilham. The network helps show where James Gilham may publish in the future.
No co-authors to show.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial and updated meta-analysis Hit paper breakdown → | 2022 | 231 |
| 2 | Higher dose corticosteroids in patients admitted to hospital with COVID-19 who are hypoxic but not requiring ventilatory support (RECOVERY): a randomised, controlled, open-label, platform trial Hit paper breakdown → | 2023 | 84 |
| 3 | 2023 | 25 | |
| 4 | 2024 | 24 | |
| 5 | 2022 | 17 | |
| 6 | 2022 | 6 | |
| 7 | 2025 | 5 |
About James Gilham
James Gilham is a scholar working on Infectious Diseases, Endocrinology, Diabetes and Metabolism, Surgery, Nuclear Energy and Engineering and Waste Management and Disposal, having authored 7 papers that have together received 392 indexed citations. Recurring topics across this work include COVID-19 Clinical Research Studies (5 papers), Diabetes Treatment and Management (1 paper) and Kawasaki Disease and Coronary Complications (1 paper). The work is most often cited by research in Infectious Diseases (230 citations), Endocrinology, Diabetes and Metabolism (28 citations), Pulmonary and Respiratory Medicine (28 citations), Epidemiology (28 citations) and Geriatrics and Gerontology (3 citations). James Gilham has collaborated with scholars based in United Kingdom. Their work appears in journals such as The Lancet, Cardiovascular Diabetology, Diabetes Care, The Lancet Infectious Diseases and The Lancet Diabetes & Endocrinology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.